CardiologyOnline.net

Cardiology Xagena

Search results for "Antiplatelet therapy"

Study treatments for the ACTIVE W trial of the ACTIVE ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) program have been discontinued due to a significant di ...


Aspirin and Clopidogrel ( Plavix ) are platelet antiaggregant drugs widely used and proven to be effective in the treatment of an acute coronary syndrome ( ACS ). High-risk patients with non-ST segme ...


A large international study has demonstrated that patients with atherothrombosis ( coronary artery disease, cerebrovascular disease, peripheral arterial disease ) often have cardiovascular risk factor ...


A large international study has demonstrated that patients with atherothrombosis ( coronary artery disease, cerebrovascular disease, peripheral arterial disease ) often have cardiovascular risk factor ...


Results from the CHARISMA ( Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance ) trial showed an excess mortality in patients randomized to Clopidogrel ( P ...


Patients who receive the anti-platelet medication Clopidogrel ( Plavix ) following an acute coronary syndrome appear to be at greater risk of a heart attack or death in the first 90 days after stoppin ...


Prasugrel ( Efient, Effient ), a new antiplatelet agent that provides higher levels of platelet inhibition than current standard therapies, could provide more consistent protection from ischemic event ...


Prasugrel ( Efient, Effient ), a new antiplatelet agent that provides higher levels of platelet inhibition than current standard therapies, could provide more consistent protection from ischemic eve ...


The routine use of Acetylsalicylic acid ( Aspirin ) for the primary prevention of vascular events in people with asymptomatic disease cannot be supported, according to results from the Aspirin for Asy ...


Heightened platelet activity plays a critical role in thrombus formation, which is central to acute coronary syndromes ( ACS ), including non-ST-segment elevation ( NSTE )-ACS ( comprising unstable an ...


A randomised multicentre open-label study was evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months' duration of dual therapy ...


The oral anticoagulant Xarelto ( Rivaroxaban ) has been approved by the European Commission for the prevention of atherothrombotic events ( cardiovascular death, myocardial infarction or stroke ) afte ...


The European Committee for Medicinal Products for Human Use ( CHMP ) has recommended approval of oral anticoagulant Xarelto ( Rivaroxaban ) 2.5 mg twice-daily in combination with standard antiplatelet ...


Drug-eluting stents with durable biocompatible or biodegradable polymers have been developed to address the risk of thrombosis associated with first-generation drug-eluting stents.The aim of a study w ...


If percutaneous coronary intervention ( PCI ) is required in patients taking oral anticoagulants, antiplatelet therapy with Acetylsalicylic acid ( Aspirin ) and Clopidogrel ( Plavix ) is indicated, bu ...